Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Enterprise Value (2018 - 2025)

Historic Enterprise Value for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$3.1 million.

  • BioNexus Gene Lab's Enterprise Value fell 1625.58% to -$3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 1625.58%. This contributed to the annual value of -$5.7 million for FY2024, which is 2574.76% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Enterprise Value stood at -$3.1 million, which was down 1625.58% from -$3.8 million recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Enterprise Value high stood at -$1.1 million for Q1 2025, and its period low was -$6.1 million during Q3 2023.
  • Over the past 5 years, BioNexus Gene Lab's median Enterprise Value value was -$2.1 million (recorded in 2021), while the average stood at -$2.9 million.
  • As far as peak fluctuations go, BioNexus Gene Lab's Enterprise Value plummeted by 32036.61% in 2023, and later surged by 8129.0% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Enterprise Value stood at -$2.1 million in 2021, then rose by 0.24% to -$2.1 million in 2022, then crashed by 113.21% to -$4.5 million in 2023, then decreased by 25.75% to -$5.7 million in 2024, then soared by 45.46% to -$3.1 million in 2025.
  • Its Enterprise Value was -$3.1 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$1.1 million in Q1 2025.